Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Cash & Equivalents: 2017-2020

Historic Cash & Equivalents for Cogent Biosciences (COGT) over the last 4 years, with Dec 2020 value amounting to $242.2 million.

  • Cogent Biosciences' Cash & Equivalents rose 56.77% to $202.9 million in Q3 2021 from the same period last year, while for Sep 2021 it was $202.9 million, marking a year-over-year increase of 56.77%. This contributed to the annual value of $242.2 million for FY2020, which is 547.15% up from last year.
  • Latest data reveals that Cogent Biosciences reported Cash & Equivalents of $242.2 million as of FY2020, which was up 547.15% from $37.4 million recorded in FY2019.
  • In the past 5 years, Cogent Biosciences' Cash & Equivalents registered a high of $242.2 million during FY2020, and its lowest value of $36.9 million during FY2017.
  • Its 3-year average for Cash & Equivalents is $118.2 million, with a median of $75.0 million in 2018.
  • In the last 5 years, Cogent Biosciences' Cash & Equivalents slumped by 50.12% in 2019 and then spiked by 547.15% in 2020.
  • Cogent Biosciences' Cash & Equivalents (Yearly) stood at $36.9 million in 2017, then spiked by 103.39% to $75.0 million in 2018, then plummeted by 50.12% to $37.4 million in 2019, then soared by 547.15% to $242.2 million in 2020.